Treats hypertension. ANDA 78457, held by Invagen Pharms. Quinapril Hydrochloride.
As of Nov 16, 2026, ANDA 78457 (Quinapril Hydrochloride), held by Invagen Pharms, was first approved by FDA on Aug 24, 2007, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hypertension Quinapril is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 24, 2007 | Original application | Approved | None posted |
| Quinapril HydrochlorideEQ 5MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Quinapril HydrochlorideEQ 10MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Quinapril HydrochlorideEQ 20MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Quinapril HydrochlorideEQ 40MG BASE · tablet;oral | Quinapril Hydrochloride | Discontinued |
| Nov 6, 2019 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 25, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 25, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 17, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 28, 2010 | Supplement 2Labeling | Approved | None posted |
| Aug 24, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters